Frus­trat­ed Eli Lil­ly may have to set­tle for a lone­ly last-place fin­ish in the block­buster CDK 4/6 race

A frus­trat­ed Eli Lil­ly will have to wait pa­tient­ly for its close­ly-watched Phase III study of the CDK 4/6 breast can­cer drug abe­maci­clib to wrap up next year be­fore it gets the fi­nal read out on its ef­fect on sur­vival rates. The phar­ma gi­ant re­port­ed that the piv­otal tri­al will have to con­tin­ue “as the in­ter­im ef­fi­ca­cy cri­te­ria were not met.”

Fi­nal re­sults are now ex­pect­ed some­time in the first half of 2017, which could de­lay a launch in­to 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.